drugset / Trial / NCT00638859

Japanese Study Evaluating the Effects of Telithromycin in Children With Community-Acquired Pneumonia

NCT00638859

Phase 3 Completed 56 enrolled Sanofi
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary objective is to assess the safety of telithromycin (HMR3647) 20 mg/kg qd for 5-7 days in children with community-acquired pneumonia (CAP). Secondary objectives are to assess Pharmacokinetics, Efficacy and Acceptability of telithromycin 20 mg/kg qd for 5-7 days in children with CAP.

Timeline

Start
2004-03
Primary completion
2004-10
Completion
2004-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Telithromycin Small molecule 20 mg/kg

Indications